

Janssen-Cilag Pty Ltd  
ABN 47 000 129 975



507 Mt Wellington Highway,  
Mt Wellington, Auckland 1060  
New Zealand  
P.O. Box 62185, Sylvia Park Auckland 1644  
Toll free tel: 0800 800 806  
Fax: 649 588 1398

[www.janssen.com/newzealand/](http://www.janssen.com/newzealand/)

April 1, 2020

## **Discontinuation of REOPRO<sup>®</sup> (abciximab) 10mg/5mL solution for injection vials as of 30 June 2020**

Dear Healthcare Professional,

Janssen-Cilag Pty Ltd ('Janssen') would like to advise you that due to the cessation of supply worldwide we are discontinuing supply of REOPRO<sup>®</sup> (abciximab) 10mg/5mL solution for injection vials in New Zealand from the 30<sup>th</sup> of June 2020.

REOPRO<sup>®</sup> 10mg/5mL solution for injection vials contain the active ingredient abciximab. REOPRO<sup>®</sup> is indicated as an adjunct to heparin and aspirin for:

1. Percutaneous coronary intervention: The prevention of ischaemic cardiac complications (death, myocardial infarction or need for urgent intervention) in patients during or following percutaneous coronary intervention (balloon angioplasty, atherectomy and stent placement).
2. Unstable angina: The stabilisation of unstable angina patients not responding to conventional medical therapy who may be candidates for percutaneous coronary intervention.

Please refer to the REOPRO<sup>®</sup> Data Sheet should you need any information on this product, available at <https://www.janssen.com/newzealand/our-medicines> or <https://www.medsafe.govt.nz/profs/Datasheet/datasheet.htm>.

Given REOPRO<sup>®</sup> 10mg/5mL solution for injection vials will not be available after June 30<sup>th</sup> 2020, we recommend that healthcare professionals and hospitals review current protocols and consider treating patients with other available glycoprotein IIb/IIIa antagonists instead of REOPRO<sup>®</sup>. Janssen apologizes for any inconvenience caused to you or your patients.

Janssen is committed to monitoring the safety of our products. We encourage healthcare professionals to report any suspected adverse events for our products to the Centre for Adverse Reactions Monitoring via either their online reporting form, available at <https://nzphvc.otago.ac.nz/report/>, by phone on 03 479 7247 or by email at [carmnz@otago.ac.nz](mailto:carmnz@otago.ac.nz).

If you have further questions, please contact Janssen Medical Information on 0800 800 806 or via email at [medinfo@janau.jnj.com](mailto:medinfo@janau.jnj.com).

Sincerely

A handwritten signature in black ink, consisting of a series of loops and a long horizontal stroke extending to the right.

Dr Sophie Glover-Koudounas  
Executive Director, Medical & Scientific Affairs ANZ  
Janssen-Cilag Pty Ltd